The Comparison of Thyroarytenoid Muscle Myectomy and Type II Thyroplasty for Spasmodic Dysphonia

Nomoto, Masaki; Tokashiki, Ryoji; Hiramatsu, Hiroyuki; Konomi, Ujimoto; Motohashi, Rei; Sakurai, Eriko; Toyomura, Fumimasa; Ueda, Yoshio; Inoue, Shun; Tsukahara, Kiyoaki; Suzuki, Mamoru

doi:10.1016/j.jvoice.2014.09.030

Cited by 23 publications

(32 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our group level results are in line with those published in previous studies, which found a beneficial effect of TA myoneurectomy 1 year after the procedure . However, during further follow‐up (after 18 months on average), 10 of the 22 patients (45%) eventually needed a second procedure because of recurrence of their dystonic voice problem.…”

Section: Discussionsupporting

confidence: 90%

“…Voice outcome was assessed using the validated Voice Handicap Index (VHI) and a nonvalidated patient‐reported questionnaire on voice‐related topics. The VHI, developed by Jacobson and Grywalski and validated for the Dutch language by Verdonck‐de Leeuw et al, consists of 30 items designed to assess how patients perceive their voice from three aspects: functionally, physically, and psychologically . Each response is scored from 0 (no complaints) to 4 (maximal complaints), with a final score ranging from 0 to 120 .…”

Section: Methodsmentioning

confidence: 99%

“…Nomoto et al compared the outcomes of TP II with TA myoneurectomy . Voice quality improved in both procedures, but significant differences in severity outcomes favoring TA myoneurectomy were found in strangulation, interruption, tremor, and grade . Another advantage of TA myoneurectomy is the relative simplicity of the standard endoscopic laser procedure, which does not require a cervical incision.…”

Section: Introductionmentioning

confidence: 99%

“…Although several surgical techniques have been described, over the last 10 years the majority of literature reports on two commonly performed surgical procedures: thyroplasty type II (TP II) and endoscopic laser thyroarytenoid (TA) myoneurectomy. 9 TP II is a procedure that relieves the symptoms of AdSD by decreasing the excessive closure of the glottis by dividing and separating the thyroid cartilage in the midline and fixing it with a silicone shim or titanium bridge to slightly widen the distance between the vocal fold at the level of the anterior commissure. 5,[10][11][12] This is in contrast to a TA myoneurectomy procedure, which targets the end organ of AdSD by removing the thyroarytenoid muscle, terminal nerves, and neuromuscular junction.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Adductor spasmodic dysphonia: Botulinum toxin a injections or laser thyroarytenoid myoneurectomy? A comparison from the patient perspective

et al. 2019

View full text Add to dashboard Cite

Objectives/Hypothesis The current gold standard of therapy for adductor spasmodic dysphonia (AdSD) is injection of botulinum toxin A (BTX) in the adductor musculature. A surgical procedure could potentially offer more stable and long‐lasting voice quality. In this study, we report the long‐term results of endoscopic laser thyroarytenoid (TA) myoneurectomy versus BTX treatment in the same patients with AdSD. Study Design Retrospective case series. Methods Between July 2013 and September 2016, a total of 22 patients with AdSD were included. Voice outcomes were measured using the Voice Handicap Index and a Likert‐scale patient‐reported voice questionnaire. Data were obtained for each patient at four time points: preoperatively with and without BTX and twice postoperatively at 3 months (short term) and 12 months (long term). Results No statistically significant differences were found between voice outcome after BTX injection and the short‐ and long‐term postoperative voice outcomes for the group as a whole. During postoperative follow‐up, 10 of the 22 patients (45%) needed a second procedure after an average of 18 months (interquartile range, 13–22 months) due to recurrence of their original voice problem. Conclusions The TA myoneurectomy showed encouraging results, comparable to BTX after follow‐up of 12 months for the group as a whole. However, after good results initially, voice deterioration was seen in 45% of the patients who all underwent a second procedure. These preliminary results provide important insights into the value of TA myoneurectomy as a potential definite treatment for a select group of patients with AdSD. Further research might explore long‐term results after revision surgery. Level of Evidence 4 Laryngoscope, 130:741–746, 2020

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Adductor spasmodic dysphonia: Botulinum toxin a injections or laser thyroarytenoid myoneurectomy? A comparison from the patient perspective

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Treatment for SD includes alcohol [35], surgery [10, 36,37], neuromodulation [38] and intra-laryngeal injections of BoNT-A with various injection techniques using electromyography guidance (EMG) [16,39,40]. Dosages and titrations of BoNT-A are also being investigated check [41][42][43][44].…”

Section: A Qualitative Study [32] Of Expert and Everyday Listener's Pmentioning

confidence: 99%

Review of differential diagnosis and management of spasmodic dysphonia

Whurr

Lorch

2016

Current Opinion in Otolaryngology & Head and Neck Surgery

View full text Add to dashboard Cite

Purpose of Review: The recent literature on spasmodic dysphonia is reviewed with regard to pathogenesis, differential diagnosis, treatment options, audits, and current methods of which impinges on all aspects of their lives. Spasmodic dysphonia is now classified as a "rare" disease in the USA. This designation will assist in international standards of diagnosis, assessment, treatment, and management.

show abstract

Comparison of Botulinum Toxin Injections and Type 2 Thyroplasty for Adductor Spasmodic Dysphonia

Sanuki

Takemoto

2023

The Laryngoscope

View full text Add to dashboard Cite

ObjectivesInjection of botulinum toxin type A (BTX) into intrinsic laryngeal muscles is the current gold standard therapy for adductor spasmodic dysphonia (AdSD). However, a surgical procedure could potentially offer more stable and long‐lasting voice quality to AdSD patients. Here, we report the long‐term results of type 2 thyroplasty (TP2) with TITANBRIDGE® (Nobelpharma, Tokyo, Japan) compared with those of BTX injections.MethodsIn total, 73 AdSD patients visited our hospital between August 2018 and February 2022. Patients were provided the option of BTX injections or TP2. They were assessed via the Voice Handicap Index (VHI)‐10 before treatments and at scheduled clinical follow‐ups at 2, 4, 8, and 12 weeks for BTX and at 4, 12, 26, and 52 weeks for TP2.ResultsOverall, 52 patients selected the BTX injection and had a pre‐injection mean VHI‐10 score of 27.3 ± 8.8. Following injections, the scores significantly improved to 21.0 ± 11.1, 18.6 ± 11.5, and 19.4 ± 11.7 at 2, 4, and 8 weeks, respectively. There were no significant differences between the pre‐injection scores and the 12‐week scores (21.5 ± 10.7). Alternately, 32 patients opted to be treated with TP2 and had a pre‐treatment mean VHI‐10 score of 27.7. All patients reported an improvement in their symptoms. Additionally, the mean VHI‐10 score significantly improved to 9.9 ± 7.4 at 52 weeks following treatment. There was a significant difference between the two treatment groups at 12 weeks. Some patients received both treatments.ConclusionThese preliminary results provide important insights into the value of TP2 as a potential permanent treatment for AdSD patients.Level of EvidenceIII Laryngoscope, 2023

show abstract

The Comparison of Thyroarytenoid Muscle Myectomy and Type II Thyroplasty for Spasmodic Dysphonia

Cited by 23 publications

References 16 publications

Adductor spasmodic dysphonia: Botulinum toxin a injections or laser thyroarytenoid myoneurectomy? A comparison from the patient perspective

Adductor spasmodic dysphonia: Botulinum toxin a injections or laser thyroarytenoid myoneurectomy? A comparison from the patient perspective

Review of differential diagnosis and management of spasmodic dysphonia

Comparison of Botulinum Toxin Injections and Type 2 Thyroplasty for Adductor Spasmodic Dysphonia

Contact Info

Product

Resources

About